MAM
SPRY icon

Marquette Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Marquette Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31,083
Closed -$132K – 372
2022
Q2 		$132K Buy
+31,083
New +$108K 0.04% 107

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Marquette Asset Management's SPRY Position: Q3 2022 in Review

Marquette Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2022, closing a stake of 31,083 shares — an estimated $132K sold.

Marquette Asset Management first reported a position in SPRY in Q2 2022 and held it in 1 quarter. The position peaked at $132K in Q2 2022. 61 funds tracked by Wall St. Rank hold SPRY as of Q3 2022.

  • Marquette Asset Management reported no remaining ARS Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Marquette Asset Management sold 31,083 ARS Pharmaceuticals shares in Q3 2022, an estimated $132K.
  • Marquette Asset Management first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Marquette Asset Management's ARS Pharmaceuticals position peaked at $132K in Q2 2022.
  • 61 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2022.

Based on Marquette Asset Management's 13F filing for Q3 2022, filed 6 Oct 2022.